FR14C0025I2 - LIQUID PREPARATIONS OF CANNABINOIDS FOR MUCOSAL ADMINISTRATION - Google Patents

LIQUID PREPARATIONS OF CANNABINOIDS FOR MUCOSAL ADMINISTRATION

Info

Publication number
FR14C0025I2
FR14C0025I2 FR14C0025C FR14C0025C FR14C0025I2 FR 14C0025 I2 FR14C0025 I2 FR 14C0025I2 FR 14C0025 C FR14C0025 C FR 14C0025C FR 14C0025 C FR14C0025 C FR 14C0025C FR 14C0025 I2 FR14C0025 I2 FR 14C0025I2
Authority
FR
France
Prior art keywords
cannabinoids
formulation
solvent
liquid preparations
mucosal administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0025C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218930A external-priority patent/GB2392093B/en
Priority claimed from US10/218,989 external-priority patent/US6946150B2/en
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of FR14C0025I1 publication Critical patent/FR14C0025I1/fr
Application granted granted Critical
Publication of FR14C0025I2 publication Critical patent/FR14C0025I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump spray. In particular , the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments comprising one or more cannabinoids via mucosal surfaces, comprising: at least one lipophilic medicament which comprises one or more cannabinoids, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation, the formulation is absent of a self-emulsifying agent and/or fluorinated propellant, and the cannabinoid(s) is/are present in the formulation in an amount greater than 10 mg/ml.
FR14C0025C 2002-08-14 2014-03-21 LIQUID PREPARATIONS OF CANNABINOIDS FOR MUCOSAL ADMINISTRATION Active FR14C0025I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0218930A GB2392093B (en) 2002-08-14 2002-08-14 Pharmaceutical formulations
US10/218,989 US6946150B2 (en) 2002-08-14 2002-08-14 Pharmaceutical formulation
PCT/GB2003/003574 WO2004016246A1 (en) 2002-08-14 2003-08-14 Cannabinoid liquid formulations for mucosal amdinistration

Publications (2)

Publication Number Publication Date
FR14C0025I1 FR14C0025I1 (en) 2014-08-08
FR14C0025I2 true FR14C0025I2 (en) 2014-11-14

Family

ID=31889678

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0025C Active FR14C0025I2 (en) 2002-08-14 2014-03-21 LIQUID PREPARATIONS OF CANNABINOIDS FOR MUCOSAL ADMINISTRATION

Country Status (16)

Country Link
EP (2) EP2314284B1 (en)
JP (1) JP4515908B2 (en)
KR (1) KR101008609B1 (en)
AT (1) ATE533472T1 (en)
AU (2) AU2003253005B2 (en)
CA (1) CA2454644C (en)
CY (1) CY1112523T1 (en)
DK (2) DK1542657T3 (en)
ES (2) ES2625605T3 (en)
FR (1) FR14C0025I2 (en)
LU (1) LU92233I2 (en)
MX (1) MXPA05001567A (en)
PL (1) PL215220B1 (en)
PT (2) PT2314284T (en)
SI (1) SI1542657T1 (en)
WO (1) WO2004016246A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE353629T1 (en) 2000-03-09 2007-03-15 Gw Pharma Ltd PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABIS
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2434312B (en) * 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
US9035130B2 (en) 2007-05-31 2015-05-19 Gw Pharma Limited Reference plant, a method for its production, extracts obtained therefrom and their use
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (en) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
GB2491118B (en) 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496688B (en) * 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US8741341B2 (en) * 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
US20160015818A1 (en) * 2014-07-18 2016-01-21 Medipath, Inc. Compositions and methods for physiological delivery using cannabidiol
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EA201790880A1 (en) 2014-10-21 2017-08-31 Юнайтед Кэннэбис Корп. EXTRACTS OF CONOPLI AND METHODS OF THEIR RECEPTION AND APPLICATION
DK3236967T3 (en) 2014-12-22 2020-01-02 Suda Pharmaceuticals Ltd PREVENTION AND TREATMENT OF METASTATIC DISEASE OF CANCER PATIENTS WITH TROMBOCYTOSIS
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
CN109475586A (en) 2016-06-29 2019-03-15 康纳塞斯创新公司 The cannabis resin of decarboxylation, its purposes and the method for preparing it
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US10188628B1 (en) 2016-10-27 2019-01-29 Alvin Kershman Release composition for derivatives of Cannabaceae
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
WO2018176055A2 (en) 2017-03-24 2018-09-27 Trait Biosciences, Inc. High level in vivo biosynthesis and isolation of water-soluble cannabinoids in plant systems
US11905543B2 (en) 2017-07-11 2024-02-20 Trait Biosceinces, Inc. In vivo generation of water-soluble acetylated cannabinoid glycoside compounds in plant cell suspension cultures
CN111465700A (en) 2017-07-11 2020-07-28 特征生物科学公司 Water soluble cannabinoid compounds and material compositions in yeast and plant cell suspension cultures
US11946059B2 (en) 2017-07-11 2024-04-02 Trait Biosciences, Inc. In vivo generation of water-soluble cannabinoids in plant cell suspension cultures
EP3681525A4 (en) * 2017-09-15 2020-09-02 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
US20200289459A1 (en) * 2017-11-30 2020-09-17 Canopy Growth Corporation Liquid dosage forms, methods of making and use
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
CA3103504A1 (en) * 2018-06-15 2019-12-19 CannPal Animal Therapeutics Limited Cannabinoid composition and methods of treatment using the same
US11504416B2 (en) 2018-09-04 2022-11-22 Paw Power, Inc. Formulation with cannabinoids
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
WO2020223800A1 (en) * 2019-05-03 2020-11-12 Zyus Life Sciences Inc. Formulation for pain management
WO2021016343A1 (en) * 2019-07-22 2021-01-28 Good Design, Inc. Cartridge for dispensing products and methods for their manufacture
WO2021055937A1 (en) * 2019-09-20 2021-03-25 Good Design, Inc. Cartridge for dispensing products and methods for their manufacture
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
AU2021318553A1 (en) 2020-07-28 2023-03-23 Impello Biosciences Inc. Methods and compositions for altering secondary metabolites in plants
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
CA3199891A1 (en) 2020-11-24 2022-06-02 Ruth Gallily Cannabinoid derivatives and their use for the treatment of inflammation and/or pain and/or obesity
KR102489407B1 (en) * 2021-01-18 2023-01-17 주식회사 네이처센스 COMPOSITION FOR pain relief AND PREVENTING OR ALLEVIATING STRESS-INVOLVED DISEASE COMPRISING Extract of CANNABIS SATIVA L.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560625A (en) 1967-02-20 1971-02-02 Colgate Palmolive Co Method of,and formulations for,introducing alkoxybenzamides into the systemic circulatory system
DE3522550A1 (en) 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab SPRAYABLE PHARMACEUTICAL PREPARATION FOR TOPICAL APPLICATION
US5165093A (en) * 1992-03-23 1992-11-17 The Titan Corporation Interstitial X-ray needle
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
WO2001003668A1 (en) * 1999-07-08 2001-01-18 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Pulmonary delivery of liposome-encapsulated cannabinoids
DE19936911A1 (en) 1999-08-05 2001-02-08 Henkel Kgaa Colorant for keratinous fibers, especially human hair, contains coloring component combination of amino-substituted aromatic aldehyde or ketone and methyne-active compounds
MXPA02001804A (en) * 1999-08-20 2004-09-06 Unimed Pharmaceuticals Inc Composition for inhalation comprising delta 9 tetrahydrocannabinol in a semiaqueous solvent.
GB9927555D0 (en) * 1999-11-23 2000-01-19 Bede Scient Instr Ltd X-ray fluorescence apparatus
ATE353629T1 (en) 2000-03-09 2007-03-15 Gw Pharma Ltd PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABIS
WO2002058636A2 (en) * 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
HU227452B1 (en) 2001-02-14 2011-06-28 Gw Pharma Ltd Mucoadhesive pharmaceutical formulation
EP1321159A1 (en) * 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices

Also Published As

Publication number Publication date
FR14C0025I1 (en) 2014-08-08
CY1112523T1 (en) 2015-12-09
AU2009202434B2 (en) 2012-08-30
AU2003253005B2 (en) 2009-03-19
EP2314284A3 (en) 2012-05-09
EP2314284A2 (en) 2011-04-27
DK2314284T3 (en) 2017-05-22
AU2003253005A1 (en) 2004-03-03
KR101008609B1 (en) 2011-01-17
ATE533472T1 (en) 2011-12-15
KR20050042157A (en) 2005-05-04
WO2004016246A1 (en) 2004-02-26
AU2009202434A1 (en) 2009-07-09
EP1542657A1 (en) 2005-06-22
ES2625605T3 (en) 2017-07-20
MXPA05001567A (en) 2005-04-25
SI1542657T1 (en) 2012-04-30
JP4515908B2 (en) 2010-08-04
EP2314284B1 (en) 2017-02-15
EP1542657B1 (en) 2011-11-16
JP2006504671A (en) 2006-02-09
EP1542657B8 (en) 2012-03-14
PT2314284T (en) 2017-05-25
LU92233I2 (en) 2013-08-26
PL375224A1 (en) 2005-11-28
CA2454644A1 (en) 2004-02-14
PL215220B1 (en) 2013-11-29
ES2377819T3 (en) 2012-04-02
CA2454644C (en) 2014-09-16
PT1542657E (en) 2012-02-29
DK1542657T3 (en) 2012-03-05

Similar Documents

Publication Publication Date Title
FR14C0025I2 (en) LIQUID PREPARATIONS OF CANNABINOIDS FOR MUCOSAL ADMINISTRATION
US6432415B1 (en) Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
US20190374508A1 (en) Therapeutic topical compositions of apremilast
EP2343045A3 (en) Transmucosal drug delivery system
DE60126599D1 (en) CANNABIS CONTAINING PHARMACEUTICAL COMPOSITIONS
ES2089011T3 (en) LIPIDIC EXCIPIENT OF NASAL ADMINISTRATION AND TOPICAL APPLICATION.
KR950007859A (en) Rapamycin formulations for oral administration
FI20000172A (en) Pharmaceutical composition in the form of a self-emulsifying formulation for acidic lipophilic compounds
EA199900991A1 (en) MEDICAL SPRAY PREPARATIONS
KR970032872A (en) Drugs for the treatment of skin damage containing acetylsalicylic acid
BR0109747A (en) Use of 5- (2-pyrazinyl) -4-methyl-1-2-dithiol-3-thione (oltipraz) as a medicine, pharmaceutical composition for the prevention and treatment of hepatic fibrosis progression, use of 5- (2- pyrazinyl) -4-methyl-1,2-dithiol-3-thione and method for the prevention and treatment of fibrosis progression and liver cirrhosis
MY126358A (en) Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
MA28419B1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF A PYRAZOLE-3-CARBOXAMIDE DERIVATIVE
JP2003081812A (en) Aerosol preparation
WO2009070829A1 (en) Non-aqueous oil-based fentanyl compositions for transmucosal administration
JP2006527764A (en) Nasal microemulsion containing diazepam
JP2001039922A (en) Inhibition of decomposition of sorbic acids, and liquid preparation composition
TH63200A (en) Liquid Entecave Formulation with Low Dosage and Use
MX9604004A (en) Aerosol drug formulations containing vitamin e.
TH18778A (en) Formulation for an oral pharmaceutical chemical